AGS-TX

2-billion-years-old

technology, unleashed.

Extracellular Vesicles from Microalgae (MEV)
as Drug Delivery Systems for Human Therapeutics.

As a Biopharmaceutical Company, we genetically engineer the billion-years-old natural machinery of microalgae to develop therapeutics.

AGS THERAPEUTICS
AGS-TX

2-billion-year-old

technology, unleashed .
Extracellular Vesicles from Microalgae (MEV)
as Drug Delivery Systems for Human Therapeutics.

As a Biopharmaceutical Company, we engineer the billion-years-old natural machinery of microalgae to develop therapeutics delivered by microalgae extracellular vesicles (MEVs).

AGS THERAPEUTICS
TIMES
Awarded template of the year 2021
GOOD
COMPANY
Best rated Webflow template
App Store
Customer Reviews
STARTUP
REPORT
Easy to use and to customize
QUICK
REPORT
Clean and minimalist design
AGS-TX

2-billion-year-old technology, live.

AGS THERAPEUTICS

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.

TIMES
Awarded template of the year 2021
GOOD
COMPANY
Best rated Webflow template
App Store
Customer Reviews
STARTUP
REPORT
Easy to use and to customize
QUICK
REPORT
Clean and minimalist design
Easy to Use

Rerum facilis est et expedita distinctio nam libero

Fast response

Rerum facilis est et expedita distinctio nam libero

Friendly UI

Rerum facilis est et expedita distinctio nam libero

Explore our platform of siRNA therapeutics

R&D programs

As dramatically seen with the current COVID-19 pandemic, therapeutics against viral and bacterial infections still represent a significant medical problem as new or resistant pathogens emerge. There is a vast, urgent, unmet need to bring rapid and adapted solutions against emerging diseases.

AGS-01 P.aeruginosa

AGS-01 P.aeruginosa

AGS-01 is a siRNA population targeting multiple regions, simultaneously, against P. aeruginosa, namely essential genes, virulence factors, and antibiotic resistance genes.

AGS-02 S.aureus

AGS-02 S.aureus

AGS-02 is a siRNA population targeting multiple regions, simultaneously, against S. aureus, covering essential genes, virulence factors, and antibiotic resistance genes.

AGS-03 Antiviral - demonstration

AGS-03 Antiviral - demonstration

AGS-03 is a siRNA population targeting multiple viral regions simultaneously against SARS-CoV-2, more specifically sixteen regions of the viral genome and host regulatory genes.

AGS-01 P.aeruginosa

AGS-01

P. aeruginosa

AGS-01 is a siRNA population targeting multiple regions, simultaneously, against P. aeruginosa, namely essential genes, virulence factors, and antibiotic resistance genes.

AGS-02 S.aureus

AGS-02

S. aureus

AGS-02 is a siRNA population targeting multiple regions, simultaneously, against S. aureus, covering essential genes, virulence factors, and antibiotic resistance genes.

AGS-03 Antiviral - demonstration

AGS-03

Antiviral - demonstration

AGS-03 is a siRNA population targeting multiple viral regions simultaneously against SARS-CoV-2, more specifically sixteen regions of the viral genome and host regulatory genes.

AGS-TX

Technology Platform

Our highly versatile, proprietary technology platform can be applied to a diversity of targets and purposes. As part of our initial focus on anti-infectives, we develop microalgae-induced gene silencing therapeutics, delivered by microalgae extracellular vesicles, aimed at killing or blocking the replication of human pathogens.

MIGs Platform

Microalgae Genetic Engineering

Our proprietary platform enables the generation of stable producer cell lines from genetically engineered microalgae, for therapeutics applications. The microalgae are then used to express custom, targeted RNAi (siRNA or miRNA) which are directly embedded, by the same microalgae, into their own extracellular vesicles.

RNAi Biotherapeutics

Antimicrobial Precision Killing

The therapeutic agents (RNAi) produced by our initial set of microalgae cell lines are designed to be pathogen-killers independent of their antibiotic resistance (bacteria) and their immunogenicity or escape mutability (viruses). Welcome the next generation of antibacterial and antiviral biotherapeutics.

RNAi targets

Gene Silencing Shotgun

We take advantage of the versatility of RNAi, used to down-regulate the expression of target genes in specific hand-picked gene sequences, and aim at any and all regions, both structural and functional, where essential, pathogenic, or resistance genes are present.
All the action happens simultaneously, like a shotgun.

MEVs

Natures’ own Delivery System

True to EVs’ natural role as primary communication channel between cells, we engineered our microalgae-based EVs (MEVs) to serve as Drug Delivery System (DDS), to carry, protect, and deliver their cargo right into human or bacterial cells. By design, MEVs can be either generic (targeting a variety of tissues and allowing for multiple administration routes) or specific.

Safe system

The Ideal Biological System

Microalgae are free from human pathogens (e.g. viruses, mycoplasma), and their MEVs are non-toxic as well as non-immunogenic for humans. Unlike most of the current pharmaceutical industry, which uses animal cells or synthetic biology for the manufacturing of proteins, viral vectors, and EVs among others, our technology offers a safer alternative.

Simple process

The New Gold Standard

Requiring only light, water, and salts, microalgae-based biologics are produced and purified using inherently clean and simple processes, with low-to-no media supplements, that can easily be scaled-up in compliance with cGMP regulations. Equipped with cutting-edge Photo-Bioreactors (PBRs) and industry-standard Downstream Processing (DSP) tools, we achieve a high-yield, low-cost overall process.

__________________________________________________________________________________________________________
AGS-TX
THIS IS OUR COMPANY

Management team

Manuel VEGA
Founder,
CEO
Lila DRITTANTI
Founder,
COO & Product Development
Lionel NAVARRO
Founder,
Scientific Advisor
Marie-Hélène LEOPOLD
Founder,
Corporate Development CCD

Advisory Board

Eric QUEMENEUR
FR
Executive VP, CSO, TRANSGENE
(since 2014).
Director Research – Industrial Partnerships, CEA (1990 – 2014).
Charles DETAISNE
FR
CEO, ANTINEO SAS
(since 2015).
Senior Director Corporate Development, SANOFI PASTEUR, (2003 - 2015).
Alex CHANAS
UK
Non-executive Director at several health companies (since 2011).
Executive Director, Worldwide Business Development, PFIZER (1997 – 2011).
Ron NEWBOLD
USA
Chief Business Officer, SPINOGENIX Inc.
(since 2020).
Senior VP, Chief Business Officer US, OTSUKA Pharmaceutical (2017 – 2019).
VP External R&D Innovation, PFIZER (2010-2017).
Jérémy PRUVOST
FR
Director, ALGOSOLIS.
Director, GEPEA.
Head of Research, Microalgae, GEPEA (2011-2018).
Co-Director, SPI Doctoral School, Univ. Nantes (2012-2016).
Fayza DABOUSSI
FR
CSO, TWB.
Research Director, INRA.
VP, Synthetic Biology, CELLECTIS (2008-2014).
AGS-TX

PARTNERS